PECAM1 and Cerebral ischemia: Therefore, the angiogenic effects of administration of OGD-PBMCs was assessed by immunofluorescence staining of the ischemic cortex at 28 days after cerebral ischemia using an antibody against the angiogenesis marker, i.e., CD31 (Fig. 5A).